Treatment for Crohn's disease is aimed at immunosuppression.
However, inherited disorders associated with defective innate immunity often lead to development of a Crohn's-like disease.
In this study, published in the Lancet, researchers performed an open-label dose-escalation trial (4 to 8 µg per kg per day) to investigate granulocyte-macrophage colony-stimulating factor (GM-CSF) in the treatment of Crohn's disease.
The research team assessed 15 patients with moderate to severe Crohn's disease.
|Following 8 weeks of treatment with GM-CSF, mean CDAI had fallen by 190 points.|
They found that no patients had worsening of their disease.
In addition, researchers found adverse events to be negligible; these included minor injection site reactions and bone pain.
They also found that patients had a significant decrease in mean Crohn's disease activity index (CDAI) score during treatment. After 8 weeks of treatment, mean CDAI had fallen by 190 points.
Overall, 12 patients had a decrease in CDAI of more than 100 points, and 8 achieved clinical remission.
Drs Brian Dieckgraefe and Joshua Korzenik concluded, "Retreatment was effective, and treatment was associated with increased quality-of-life measures".
"GM-CSF may offer an alternative to traditional immunosuppression in treatment of Crohn's disease".